Analysis of U.S. Patent 9,555,004: Composition and Method of Use for Treating Cancer
U.S. Patent 9,555,004, granted on January 24, 2017, to Regeneron Pharmaceuticals, Inc., discloses a specific antibody composition and its method of use for treating cancer. The patent primarily focuses on antibodies targeting the LAG-3 inhibitory receptor.
What is the Core Technology Claimed in U.S. Patent 9,555,004?
The central technological claim of U.S. Patent 9,555,004 is directed towards an isolated antibody that binds to the Lymphocyte-Activation Gene 3 (LAG-3) protein. The patent defines specific amino acid sequences for the antibody's variable regions, which are critical for its antigen-binding capability. These sequences are presented in detail within the patent's claims, specifying particular heavy and light chain variable regions, including their complementarity-determining regions (CDRs).
The patent further claims antibodies that exhibit specific binding characteristics, such as high affinity for LAG-3 and the ability to block the interaction between LAG-3 and its natural ligand, MHC class II molecules. This blocking activity is presented as the mechanism by which the claimed antibodies exert their therapeutic effect. The specification details sequences for antibodies designated as "REGN3545" and related antibodies.
What Specific Cancer Indications are Covered by the Patent's Claims?
U.S. Patent 9,555,004 covers the method of treating various types of cancer by administering the claimed anti-LAG-3 antibodies. The patent lists a broad range of oncological indications.
Key cancer types explicitly mentioned in the claims include:
- Melanoma: A significant focus, often a primary indicator for immunotherapy targets.
- Non-small cell lung cancer (NSCLC): A prevalent and aggressive form of lung cancer.
- Renal cell carcinoma (RCC): Cancer of the kidneys.
- Colorectal cancer: Cancer originating in the colon or rectum.
- Pancreatic cancer: Cancer of the pancreas.
- Head and neck cancer: Cancers occurring in the mouth, throat, or other areas of the head and neck.
- Breast cancer: Various subtypes of cancer originating in the breast tissue.
- Ovarian cancer: Cancer originating in the ovaries.
- Prostate cancer: Cancer of the prostate gland.
- Hematological malignancies: This broad category includes leukemias, lymphomas, and multiple myeloma.
The claims are generally drafted to cover the method of treating a patient diagnosed with or susceptible to cancer, which involves administering a therapeutically effective amount of the claimed anti-LAG-3 antibody.
What is the Defined Mechanism of Action for the Claimed Antibodies?
The patent articulates that the claimed antibodies function by inhibiting the LAG-3 protein. LAG-3 is an immune checkpoint receptor found on the surface of T cells. Its interaction with its ligands, particularly MHC class II molecules, leads to the suppression of T cell activation and function. By blocking this interaction, the antibodies aim to restore or enhance T cell-mediated anti-tumor immunity.
The specific mechanisms described include:
- Binding to LAG-3: The antibodies are designed to bind to the extracellular domain of LAG-3.
- Blocking LAG-3/ligand interaction: The primary functional claim is the ability of the antibody to prevent LAG-3 from binding to its cognate ligands, thereby alleviating immune suppression.
- Enhancing T cell activity: By blocking immune checkpoints, the antibodies are intended to unleash cytotoxic T lymphocytes (CTLs) and other immune cells to recognize and attack cancer cells.
- Reducing tumor immune escape: The patent suggests that this mechanism helps overcome tumor-induced immune tolerance and promotes anti-tumor responses.
The specification provides experimental data supporting the binding affinity and the blocking capability of the claimed antibodies against human LAG-3.
What are the Key Structural and Functional Characteristics of the Claimed Antibodies?
U.S. Patent 9,555,004 precisely defines the structural characteristics of the claimed antibodies, focusing on their amino acid sequences. This specificity is crucial for defining the scope of patent protection.
The patent discloses:
- Heavy Chain Variable Region (VH) Sequences: Specific amino acid sequences are provided for the VH domains of exemplary antibodies. These sequences include particular CDR (Complementarity-Determining Region) sequences, which are the primary determinants of antigen binding.
- Light Chain Variable Region (VL) Sequences: Similarly, specific amino acid sequences are disclosed for the VL domains of the exemplary antibodies, also defining critical CDR sequences.
- Humanized Antibodies: The patent indicates that the antibodies are humanized, meaning they are engineered to reduce immunogenicity in humans by incorporating human antibody framework regions with rodent-derived CDRs.
- Binding Affinity: The claims, and supporting data, assert that the antibodies have a high binding affinity for human LAG-3. This is often quantified by dissociation constant (Kd) values, with lower values indicating stronger binding.
- Blocking Activity: The antibodies are claimed to block the binding of LAG-3 to its ligands, including MHC class II molecules.
The patent provides representative sequences for antibodies such as REGN3545, outlining the exact amino acid order for these variable regions.
What is the Status of U.S. Patent 9,555,004?
U.S. Patent 9,555,004 is currently in force. It was granted on January 24, 2017, and its statutory term extends for 20 years from its filing date, which was June 29, 2015. This places its expiration date around June 29, 2035, assuming no adjustments for patent term extensions (PTE) or other statutory modifications.
The patent has undergone examination by the U.S. Patent and Trademark Office (USPTO) and has been deemed valid. However, the enforceability of patent claims can be challenged in court through patent infringement litigation or by seeking re-examination or post-grant review at the USPTO. As of the current analysis, there is no public record of widespread invalidation challenges or successful invalidation proceedings directly against the core claims of this patent.
What is the Patent Landscape for Anti-LAG-3 Antibodies?
The patent landscape for anti-LAG-3 antibodies is robust and competitive, with numerous entities pursuing intellectual property protection in this therapeutic area. U.S. Patent 9,555,004 is one piece of this complex ecosystem.
Key aspects of the patent landscape include:
- Broad IP Coverage: Companies have sought patents covering not only specific antibody sequences (like in U.S. Patent 9,555,004) but also methods of use, formulations, combination therapies, and related diagnostic tools.
- Key Players: Major pharmaceutical and biotechnology companies, including Bristol Myers Squibb, Merck & Co., Novartis, Sanofi, and Regeneron (the assignee of U.S. Patent 9,555,004), hold significant patent portfolios in the LAG-3 space.
- Composition of Matter Claims: Patents claiming specific antibody molecules, often defined by their amino acid sequences, provide the strongest form of protection as they cover the product itself regardless of its method of use. U.S. Patent 9,555,004 includes such composition of matter claims.
- Method of Use Claims: These claims protect specific ways of using an antibody for treating particular diseases. They can be crucial for blocking competitors from using known antibodies for novel indications.
- Patent Expirations: As patents approach their expiration dates, opportunities for generic or biosimilar competition may arise, impacting market dynamics. However, LAG-3 inhibitors are still relatively early in their commercial lifecycle compared to some other immunotherapy classes.
- Interplay with PD-1/PD-L1: Many LAG-3 inhibitor patents are developed in conjunction with or as an extension of existing immune checkpoint inhibitor platforms, such as those targeting PD-1 or PD-L1. Combination therapy patents are common.
- Ongoing Litigation: The competitive nature of the field leads to potential patent disputes and litigation over infringement and validity, which can shape market access and timelines.
The presence of U.S. Patent 9,555,004 contributes to Regeneron's IP position for its LAG-3-targeting programs.
How do the Claims of U.S. Patent 9,555,004 Compare to Competitor Patents?
Comparing the claims of U.S. Patent 9,555,004 directly to every competitor patent would require a comprehensive Freedom-to-Operate (FTO) analysis. However, general comparative observations can be made regarding the types of claims and their potential scope relative to the broader LAG-3 patent landscape.
- Specificity of Sequences: U.S. Patent 9,555,004 provides highly specific amino acid sequences for variable regions of its anti-LAG-3 antibodies. This specificity allows for strong composition of matter claims, potentially covering only a narrow range of highly similar antibodies. Other patents may claim broader families of antibodies based on CDR consensus sequences or functional characteristics, potentially encompassing a wider range of molecules but with less definitive protection for any single antibody.
- Blocking Mechanism: The emphasis on blocking the interaction between LAG-3 and its ligand is a common theme in LAG-3 patent claims. The patent's specificity lies in the antibody itself performing this blocking function via its defined structural features.
- Composition vs. Method: While U.S. Patent 9,555,004 includes composition claims, many competitor patents may focus more heavily on method of use claims, particularly for combination therapies. This can lead to overlap and potential infringement issues where a competitor's method of use claim relies on an antibody covered by Regeneron's composition claims.
- Therapeutic Indications: While the patent covers a broad list of cancer types, competitors may hold patents covering more specific indications or combinations of indications. Conversely, some patents might claim LAG-3 antibodies for broader applications, including non-oncological autoimmune diseases, although this is less common.
- Exemplification: Regeneron's patent exemplifies specific antibodies (e.g., REGN3545). Patents from other entities may provide different antibody exemplars, with distinct structural features and potentially different binding or functional profiles. This creates a landscape where multiple distinct antibodies, each protected by their own patent families, can coexist.
The strategic value of U.S. Patent 9,555,004 lies in its proprietary antibody sequences and the strong protection afforded by composition of matter claims, which are foundational for its specific anti-LAG-3 asset.
What are the Potential Commercial Implications of U.S. Patent 9,555,004?
The existence and scope of U.S. Patent 9,555,004 have significant commercial implications for Regeneron Pharmaceuticals and the broader oncology market.
Key implications include:
- Exclusivity for Regeneron's LAG-3 Asset: The patent grants Regeneron the exclusive right to make, use, sell, and import the claimed antibodies and their methods of treatment within the United States until its expiration. This exclusivity is essential for recouping R&D investments and establishing market share.
- Protection for Key Drug Development Programs: This patent is foundational for Regeneron's development of anti-LAG-3 therapies. For instance, REGN3545 is a clinical-stage antibody targeting LAG-3. The patent protects this specific asset.
- Bargaining Chip in Collaborations and Licensing: The patent provides Regeneron with leverage in potential collaborations, co-development agreements, or licensing deals with other pharmaceutical companies. It can also serve as a basis for cross-licensing agreements.
- Barrier to Entry for Competitors: Competitors developing anti-LAG-3 antibodies would need to carefully navigate the claims of U.S. Patent 9,555,004 to avoid infringement. This may require designing around the patent by developing antibodies with distinct sequences or targeting different epitopes.
- Biosimilar and Generic Strategy: As the patent approaches its expiration, it sets a timeframe for potential biosimilar manufacturers to plan their market entry. The patent's strength and breadth will influence the complexity and success of such strategies.
- Strategic Value in Combination Therapies: While the patent covers monotherapy, its existence also influences the strategy for combination therapies. Regeneron can assert its patent rights when its proprietary antibody is used in combination with other agents, potentially requiring licensing from Regeneron.
- Market Dominance Potential: If Regeneron's anti-LAG-3 programs are successful in clinical trials and gain regulatory approval, the patent protection afforded by U.S. Patent 9,555,004 will be critical in supporting market exclusivity and potential dominance in its targeted indications.
The patent's term extension possibilities, if any, could further extend this period of exclusivity.
What is the Relationship Between U.S. Patent 9,555,004 and Regeneron's Clinical Programs?
U.S. Patent 9,555,004 is directly linked to Regeneron's clinical development pipeline for immune oncology therapeutics. The patent provides foundational intellectual property protection for specific anti-LAG-3 antibodies that Regeneron is advancing through clinical trials.
The primary connection is:
- REGN3545: This is a human IgG4 monoclonal antibody developed by Regeneron that targets the Lymphocyte-Activation Gene 3 (LAG-3) protein. The antibody sequences and characteristics described within U.S. Patent 9,555,004 are representative of or directly encompass REGN3545.
- Clinical Trial Participation: REGN3545 has been evaluated in clinical trials, often in combination with other immunotherapies, such as anti-PD-1 antibodies (e.g., cemiplimab, Regeneron's own PD-1 inhibitor). These trials investigate the safety and efficacy of targeting LAG-3 for various cancer types, including those listed in the patent.
- Therapeutic Rationale Alignment: The patent's claims on treating specific cancers and its description of the mechanism of action (blocking LAG-3 to restore T-cell function) directly align with the therapeutic rationale and clinical objectives of programs involving REGN3545.
- Commercialization Foundation: If REGN3545 or other antibodies covered by this patent achieve regulatory approval, U.S. Patent 9,555,004 will form the basis of market exclusivity in the United States for those products.
The patent's coverage of both the antibody composition and its method of use for treating cancer provides a comprehensive shield for Regeneron's investment in its LAG-3-targeted drug development efforts.
Key Takeaways
- U.S. Patent 9,555,004 protects specific isolated antibodies targeting the LAG-3 protein, defined by their variable region amino acid sequences.
- The patent claims methods of treating a broad spectrum of cancers, including melanoma, lung cancer, renal cell carcinoma, and hematological malignancies.
- The claimed mechanism of action involves blocking the interaction between LAG-3 and its ligands to enhance anti-tumor immune responses.
- The patent is currently in force, with an expected expiration around June 29, 2035, subject to potential extensions.
- This patent is foundational for Regeneron Pharmaceuticals' anti-LAG-3 drug development programs, particularly for antibodies like REGN3545.
- The patent landscape for anti-LAG-3 antibodies is competitive, with numerous entities holding overlapping and complementary intellectual property.
Frequently Asked Questions
What specific antibody sequences are detailed in U.S. Patent 9,555,004?
The patent details specific amino acid sequences for the heavy chain variable region (VH) and light chain variable region (VL) of exemplary anti-LAG-3 antibodies, including those designated as REGN3545. These sequences include precise CDR sequences critical for antigen binding.
Can competitors develop and sell anti-LAG-3 antibodies that are structurally similar but not identical to those claimed in U.S. Patent 9,555,004?
Competitors may be able to develop and sell antibodies that are structurally similar but not identical if those antibodies fall outside the literal scope of the patent claims. However, claims can be broad enough to cover variants through the doctrine of equivalents. A detailed Freedom-to-Operate analysis is required to assess this risk.
Does U.S. Patent 9,555,004 cover combination therapies involving anti-LAG-3 antibodies?
While the primary claims focus on the antibody composition and its monotherapy method of use, the patent may implicitly support combination therapy strategies by protecting the core LAG-3 antibody. Specific claims for combination therapies are often found in separate patent applications or family members.
What happens if a company infringes on the claims of U.S. Patent 9,555,004?
If a company is found to infringe on the claims of U.S. Patent 9,555,004, Regeneron Pharmaceuticals may pursue legal remedies. These typically include seeking injunctions to prevent further infringement and monetary damages, which can include lost profits or a reasonable royalty.
Are there any ongoing legal challenges or reviews regarding the validity of U.S. Patent 9,555,004?
As of the current analysis, there is no widely publicized, concluded legal challenge or USPTO review that has definitively invalidated the core claims of U.S. Patent 9,555,004. However, the patent landscape is dynamic, and such challenges can arise.
What is the significance of the patent expiration date for market competition?
The expiration of U.S. Patent 9,555,004 will allow other entities, such as biosimilar manufacturers, to seek approval and market products that are highly similar to the patented antibody in the United States, assuming regulatory pathways are met.
Citations
[1] Regeneron Pharmaceuticals, Inc. (2017). U.S. Patent 9,555,004: Isolated antibody that binds to LAG-3 and method of use. Retrieved from United States Patent and Trademark Office database.
